SCHEMBL1072841

SCHEMBL1072841

CCOC(=O)C1C(/C=C(\C)C=O)C1(C)C

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.73
TDP1 Q9NUW8 3/20 0.40
TSHR P16473 3/20 0.40
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
CYP1A2 P05177 2/20 0.38
CYP2C19 P33261 2/20 0.38
CYP3A4 P08684 1/20 0.38
CYP2D6 P10635 1/20 0.38
CYP2C9 P11712 1/20 0.38
ADRA2A P08913 1/20 0.36
CNR1 P21554 1/20 0.36
ATM Q13315 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
ALDH1A1 P00352 3/20 0.33
HSD17B10 Q99714 1/20 0.32
TP53 P04637 1/20 0.32
KDM4E B2RXH2 1/20 0.31
HTT P42858 1/20 0.31
MAPT P10636 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2167961 1.00 LMNA (0.73) LMNATDP1TSHRMEN1KMT2A
SCHEMBL1072844 1.00 LMNA (0.73) LMNATDP1TSHRMEN1KMT2A
SCHEMBL2167455 0.88 LMNA (0.56) LMNATDP1TSHRMEN1KMT2A
SCHEMBL2167462 0.88 LMNA (0.56) LMNATDP1TSHRMEN1KMT2A
SCHEMBL2167460 0.88 LMNA (0.56) LMNATDP1TSHRMEN1KMT2A
SCHEMBL3677170 0.85 LMNA (0.54) LMNATDP1TSHRMEN1KMT2A
SCHEMBL3677167 0.85 LMNA (0.54) LMNATDP1TSHRMEN1KMT2A
SCHEMBL3678630 0.85 LMNA (0.54) LMNATDP1TSHRMEN1KMT2A
SCHEMBL3678627 0.85 LMNA (0.54) LMNATDP1TSHRMEN1KMT2A
Chrysanthemic Acid, Ethyl Ester SCHEMBL3676624 0.85 LMNA (1.00) LMNATDP1TSHRMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1970368-B1 METHOD FOR PRODUCING OLEFIN COMPOUND SUMITOMO CHEMICAL CO (JP) 2012-08-29 EP disclosed
US-7985872-B2 Method for producing olefin compound SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2011-07-26 US disclosed
EP-1797953-B1 PROCESS FOR PRODUCING OXYGENIC COMPOUND SUMITOMO CHEMICAL CO (JP) 2011-01-05 EP disclosed
US-7700799-B2 Method for producing (2-formyl-1-alkenyl) cyclopropane compound SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2010-04-20 US disclosed
US-20090137839-A1 METHOD FOR PRODUCING (2-FORMYL-1-ALKENYL) CYCLOPROPANE COMPOUND SUMITOMO CHEMICAL COMPANY, LTD. (JP) 2009-05-28 US disclosed
US-7498459-B2 Method for producing (1-alkenyl)cyclopropane compound SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2009-03-03 US disclosed
US-20090036620-A1 METHOD FOR PRODUCING OLEFIN COMPOUND SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2009-02-05 US disclosed
EP-1970368-A1 METHOD FOR PRODUCING OLEFIN COMPOUND Sumitomo Chemical Company, Limited (JP) 2008-09-17 EP disclosed
US-20080064898-A1 Method for Producing Oxygen-Containing Compound SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2008-03-13 US disclosed
US-7276622-B2 Method for producing oxygen-containing compound SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2007-10-02 US disclosed
US-20070197818-A1 Method for producing (1-alkenyl) cyclopropane compound SUMITOMO CHEMICAL COMPANY, LIMITED 2007-08-23 US disclosed
EP-1797953-A1 PROCESS FOR PRODUCING OXYGENIC COMPOUND Sumitomo Chemical Company, Limited (JP) 2007-06-20 EP disclosed
EP-1728781-A1 PROCESS FOR PRODUCTION OF (1-ALKENYL)CYCLOPROPANES Sumitomo Chemical Company, Limited (JP) 2006-12-06 EP disclosed
US-20060173221-A1 Method for producing oxygen-containing compound SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2006-08-03 US disclosed
EP-1609777-A1 METHOD FOR PRODUCING OXYGEN-CONTAINING COMPOUND Sumitomo Chemical Company, Limited (JP) 2005-12-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090137839-A1 METHOD FOR PRODUCING (2-FORMYL-1-ALKENYL) CYCLOPROPANE COMPOUND ACSL3, ACSL1, ARL1 LMNA 2696/4885TDP1 4458/4885TSHR 3074/4885
US-20080064898-A1 Method for Producing Oxygen-Containing Compound AOC2, AOX1, CAT LMNA 3622/4885TDP1 4391/4885TSHR 3937/4885
US-20060173221-A1 Method for producing oxygen-containing compound GPX4, DUOX2, SCO2 LMNA 4036/4885TDP1 4530/4885TSHR 4390/4885
US-20070197818-A1 Method for producing (1-alkenyl) cyclopropane compound ACSL3, ARL1, ACSL1 LMNA 3763/4885TDP1 4490/4885TSHR 3751/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.